- Home
- AVPT vs RARE Comparison
AVPT vs RARE Comparison
Compare AVPT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | RARE |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVPT | RARE |
|---|---|---|
| Price | $12.84 | $33.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $18.38 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $393,993,000.00 | ★ $630,598,000.00 |
| Revenue This Year | $26.20 | $19.65 |
| Revenue Next Year | $18.17 | $23.65 |
| P/E Ratio | $1,622.55 | ★ N/A |
| Revenue Growth | ★ 24.71 | 20.63 |
| 52 Week Low | $11.49 | $25.81 |
| 52 Week High | $20.25 | $50.00 |
Technical Indicators
Market Signals| Indicator | AVPT | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 52.95 |
| Support Level | $12.61 | $32.06 |
| Resistance Level | $13.03 | $34.77 |
| Average True Range (ATR) | 0.33 | 1.40 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 41.41 | 67.46 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.